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The angiopoietin-like 4 (ANGPTL4) protein belongs to a superfamily of secreted proteins structurally related to factors modulating
angiogenesis known as angiopoietins. At first, ANGPTL4 has been identified as an adipokine exclusively involved in lipid
metabolism, because of its prevalent expression in liver and adipose tissue. This protein regulates lipid metabolism by inhibiting
lipoprotein lipase (LPL) activity and stimulating lipolysis of white adipose tissue (WAT), resulting in increased levels of plasma
triglycerides (TG) and fatty acids. Subsequently, ANGPTL4 has been shown to be involved in several nonmetabolic and
metabolic conditions, both physiological and pathological, including angiogenesis and vascular permeability, cell differentiation,
tumorigenesis, glucose homoeostasis, lipid metabolism, energy homeostasis, wound healing, inflammation, and redox regulation.
The transcriptional regulation ofANGPTL4 can bemodulated by several transcription factors, including PPAR훼, PPAR훽/훿, PPAR훾,
and HIF-1훼, and nutritional and hormonal conditions. Several studies showed that high levels of ANGPTL4 are associated with
poor prognosis in patients with various solid tumors, suggesting an important role in cancer onset and progression, metastasis,
and anoikis resistance. Here, we have discussed the potential role of ANGPTL4 in mediating the cross talk between metabolic
syndromes, such as diabetes and obesity, and cancer through regulation of its expression by PPARs.
1. Peroxisome Proliferator-Activated
Receptors (PPARs): Structure and Functions
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors belonging to the steroid
hormone receptor superfamily, identified for the first time
in 1990 by Issemann and Green [1]. There are three distinct
PPAR subtypes, PPAR훼, PPAR훽/훿 (also known as PPAR훽 or
PPAR훿), and PPAR훾, encoded by specific genes located on
different chromosomes. Although these three members show
a significant homology, they differ from each other for tissue
distribution, affinity for ligands, and biological functions
[2]. All subtypes are activated by endogenous ligands and
participate in the regulation of several genes involved in
glucose and lipid metabolism. However, other specific PPAR
actions are limited to specific tissue types [3, 4]. PPAR훼,
the first PPAR to be cloned, is highly expressed in tissues
characterized by elevated fatty acid oxidation such as liver,
heart, skeletal muscle, brown adipose tissue, kidney, adrenal
gland, and intestinal mucosa, where it plays a key role in the
fatty acid catabolism [5, 6]. PPAR훽/훿 is expressed in most
of human tissues, mainly in the liver, adipose tissue, skeletal
muscle, heart, brain, kidney, skin, and intestine, characterized
by an increased lipid metabolism. However, the function of
this isoform remains to be elucidated [7–10]. PPAR훾 is highly
expressed in white and brown adipose tissue (WAT and BAT)
and plays a pivotal role in the regulation of adipogenesis, fat
storage, and glucose metabolism [11–15]. In addition, PPAR훾
also regulates the expression of proinflammatory cytokines,
such as tumor necrosis factor-훼 (TNF-훼), as well as genes
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involved in insulin sensitivity. For this reason, PPAR훾 is the
main target of thiazolidinediones (TZDs), a class of drugs
used to improve lipid and glucose metabolism in type 2
diabetes [16, 17].
PPARs show a DNA binding domain (DBD) in the N-
terminal and a ligand binding domain (LBD) in the C-ter-
minal separated by a hinge region acting as a docking site
for cofactors [18]. Three PPAR isoforms exhibit an 80%
homology and are more divergent in the LBD, confirming
their different response to various ligands. After activation by
endogenous or synthetic ligands, PPARs undergo a confor-
mational change that causes the translocation to the nucleus
and the heterodimerization with another nuclear receptor,
the retinoid X receptor (RXR) [19]. The PPAR-RXR het-
erodimer then binds aDNAportion in the promoter region of
target genes, called peroxisome proliferator response element
(PPRE), modulating the expression of several genes involved
in different physiological or pathological processes [20].
Interestingly, the PPAR functions also depend on the binding
with different coactivator and corepressor proteins [21].
Indeed, after interaction with agonists, the conformational
change of the PPAR structure causes also the attachment of
coactivators and detachment of corepressors. Usually, PPAR-
RXR heterodimers are packed with a corepressor molecule
in PPRE and the binding with ligands causes an exchange
of corepressors for coactivators. One of the more studied
PPAR corepressors is histone deacetylase (HDAC). Among
the different coactivators, there are PGC-1, p300, and CREB
that are involved in regulation of metabolism as well as in
cancer development [22, 23] (Figure 1).
2. Angiopoietin-Like 4 (ANGPTL4): Structure
and Expression Patterns
The angiopoietin-like 4 (ANGPTL4) protein was discovered
for the first time in 2000 by three independent research
groups. They simultaneously identified this molecule as a
fasting-induced adipose factor (Fiaf) in different tissues.
ANGPTL4 is mainly expressed in liver and adipose tissue, as
shown by Kersten et al. [24] that highlighted its upregulation
in these tissues during fasting and a PPAR-dependent mRNA
regulation, using PPAR훼/훾 wild-type and mutant mice. Also,
Kim et al. [25] identified a novel angiopoietin-like protein
mainly expressed in hepatocytes. Finally, Cliff Yoon et al.
[26] proved the regulative relation between PPAR proteins
and ANGPTL4, demonstrating that ANGPTL4 is a target of
PPAR훾 in adipose tissue.
ANGPTL4 belongs to a superfamily of secreted pro-
teins structurally related to factors modulating angiogen-
esis known as angiopoietins (ANG). This protein family
includes eight members encoded by eight genes (ANGPTL1-
8) identified in humans and mice, except ANGPTL5, that is a
human orthologue [25, 27–29]. Only recently, in 2012, a new
feeding-induced hepatokine was identified and called RIFL/
lipasin/ANGPTL8 (also known as betatrophin) [30–33]. Just
in 2015, the HUGO gene nomenclature defined the official
name of the protein as ANGPTL8 [34]. Like angiopoietins, all
angiopoietin-like proteins (ANGPTLs) exhibit a C-terminal
fibrinogen-like globular domain and an N-terminal coiled-
coil domain [35] except for ANGPTL8. Indeed, this last
ANGPTL family member is considered an atypical member,
since it lacks the main structural features present in all other
proteins of the group, such as the fibrinogen-like domain,
glycosylation sites, and amino acids requested for formation
of disulfide bonds [32] (Figure 2). Unlike the angiopoietins,
ANGPTLs are considered orphan ligands, as they do not bind
to either the angiopoietin receptor tyrosine kinase Tie2 or the
related protein Tie1 [36–38].
The first four family members (ANGPTL1-4) and
ANGPTL6/angiopoietin-related growth factor (AGF) have
been shown to modulate angiogenesis. ANGPTLs 3, 4, 5, and
8 and ANGPTL6/AGF seem to be involved also in regulation
of other processes such as lipid metabolism and glucose and
energy homeostasis [39–46]. Another study showed that
ANGPTLs 3 and 4 control lipid metabolism by inhibiting
the activity of lipoprotein lipase (LPL) [47], an enzyme
responsible for hydrolysis of triglycerides (TG) contained
in lipoproteins, such as chylomicrons and very low-density
lipoproteins (VLDL), fatty acids, and cholesterol, whereas
ANGPTL6/AGF antagonizes obesity and related metabolic
diseases, including insulin resistance, by enhancing systemic
energy expenditure [45].
ANGPTLs show different tissue expression patterns.
ANGPTL1 is mostly detected in liver, heart, skeletal muscle,
kidney, and vessel-rich endocrine organs (adrenal glands,
thyroid, and pituitary gland) but also to a lesser extent in
uterus and gastrointestinal tract [48]. ANGPTL2 shows high
expression levels in heart, stomach, adipose tissue, skeletal
muscle, and uterus [49], whereas ANGPTL3 is predomi-
nantly expressed in liver [50, 51]. ANGPTL4 shows ∼30% of
sequence homology with ANGPTL3. It is abundantly present
in the liver, adipose tissue, and skeletal muscle and, to a lesser
extent, in placenta, small intestine, heart, and pituitary gland
[52–56]. ANGPTL5 is mainly expressed in adult human heart
[57], whereas ANGPTL6/AGF expression is restricted to liver
and plasma [58]. Lastly, ANGPTL7 exhibits high expression
levels in the cornea, neural tissues, and trabecular meshwork
as well as uterine endometrial cancer and melanoma [59].
The human gene encoding ANGPTL4 is evolutionarily
conserved among species and shares a sequence homology of∼77% with mouse. It is located on chromosome 19p13.3 and
consists of seven exons encoding a 406-amino acid glycopro-
tein. Like other proteins of the ANGPTL family, ANGPTL4
contains a C-terminal fibrinogen-like domain (cANGPTL4)
and an N-terminal coiled-coil folding domain (nANGPTL4),
in which a highly hydrophobic region that acts as a signal
peptide for protein secretion is present. In addition, it exhibits
several potential N- and O-glycosylation sites and was found
to be N-glycosylated at amino acid position 177 [37, 60].
The same domains of full-length ANGPTL4 (flANGPTL4)
protein structure were found in plasma [61, 62]. Higher-order
oligomeric structures can be formed by native flANGPTL4
through the formation of intermolecular disulfide bonds.
ANGPTL4 contains several conserved cysteine residues that
contribute to the formation of variable-sized multimeric
structures. The N-terminal oligomerization of ANGPTL4
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Figure 1: Interaction between PPARs and PPRE.The figure shows PPAR structure and related coactivator and corepressormolecules involved
in activation and repression mechanisms.The activation signaling of PPAR-RXR heterodimer and PPRE allows the expression modulation
of target molecules such as ANGPTL4.
requires the presence of two cysteine residues (Cys-76 and
Cys-80) in the N-terminal portion [63].
Different studies showed that nANGPTL4 domain is used
to modulate lipid metabolism, whereas cANGPTL4 domain
may be a modulator of tumorigenesis process [54]. Indeed,
ANGPTL4 can exert its function of LPL activity inhibitor
thanks to an oligomerization process mediated by the N-
terminal region responsible for its assembly into tetrameric
or dimeric structures [64–66]. It was hypothesized that LPL
blockage is due to 12 highly conserved amino acids that are
near the N-terminus of the protein. Indeed, mutations in
three polar amino acid residues within this region abolished
the ability of ANGPTL4 to inhibit LPL [66]. Experimental
evidence showed that several proprotein convertases, includ-
ing furin, PC5/6 (proprotein convertase 5/6), and PCSK3
(proprotein convertase subtilisin/kexin type 3), catalyze the
proteolytic processing of the human flANGPTL4 protein via
recognition of a specific amino acid sequence, causing the
release of the N-terminal region and monomeric C-terminal
portion [66, 67]. ANGPTL4 is cleaved in a tissue-dependent
manner and can be secreted into the bloodstream from
adipose tissue and liver in native and cleaved, glycosylated,
and oligomerized isoforms. In humans, the truncated form is
secreted from liver, whereas the full-length form is released
from adipose tissue [61, 62]. Furthermore, ANGPTL4 has
been shown to bind to heparin sulfate proteoglycans and
interact with ECM (extracellular matrix) proteins, by inhibit-
ing endothelial cell adhesion andmigration and altering actin
cytoskeleton [68–70].
The transcriptional regulation of ANGPTL4 and its
resulting expression can be determined by several transcrip-
tion factors, including PPAR훼, PPAR훾, and HIF-1훼. A deeper
investigation about transcription activation of ANGPTL4
and all these TFs was done by Inoue et al. [71]. Starting from
the evidence that all these factors are important angiogenic
molecules, the authors assessed whether there could be a
synergic action mechanism of these two different signals in
stimulating ANGPTL4 as angiogenesis-related target gene.
Indeed, microarray and ChiP-seq analyses showed a cross-
enhancement of ANGPTL4 expression dependent on the
conformational proximity of two response elements [71].
Different evidences showed that upregulation of
ANGPTL4 expression is strongly linked to fasting in a
variety of tissues [72, 73]. Different actors likely mediate the
“fasting effect” [74]. Several findings showed that PPARs
nuclear receptors induce an increase in ANGPTL4 expres-
sion. Glucocorticoids, whose circulating levels are high dur-
ing fasting, also seem to mediate this event [75–78], and,
in addition to fasting, chronic caloric restriction or free fatty
acids (also called NEFA) have been shown to increase plasma
ANGPTL4 levels [56]. Finally, some studies conducted on
human myofibroblasts, using genome-wide transcriptional
profiling technology, revealed that human ANGPTL4 ex-
pression might be synergistically induced by the functional
interactions of TGF-훽 and PPAR 훽/훿 signaling [79].
Since ANGPTL4 expression was found mainly in liver
and adipose tissue, this molecule was classified, at first,
as an adipokine exclusively involved in lipid metabolism.
4 PPAR Research
ANGPTL1
ANGPTL2
ANGPTL3
ANGPTL5
ANGPTL6
ANGPTL7
ANGPTL4
LIPASIN
Signal peptide
SE1
Coiled-coil domain
Fibrinogen-like domain
NN
160 188
S
280–309
S S
432–455
ANG1
NNNN
15412292 243
N
295
S S
286–315
S S
439–452
S
N
177
S
188–216
S S
341–354
S
Figure 2: Structural organization and homology between ANGPTL family members. Signal peptide domain is shown in green, specific
epitope 1 (SE1) (region present in ANGPTL3 and ANGPTL4 important for binding LPL and inhibiting its activity in vitro and in vivo) in
purple red, coiled-coil domain in blue, and N-terminal fibrinogen-like domains in orange. Glycosylation sites (N) are shown at positions 92,
122, 154, 243, and 295 for ANG1; positions 160 and 188 for ANGPTL1; and position 177 for ANGPTL4. Disulfide bonds (SS) are shown at
positions 286–315 and 439–452 for ANG1; 280–309 and 432–455 for ANGPTL1; 188–216 and 341–354 for ANGPTL4.
Afterwards, thanks to a large number of studies, this protein
has been shown to have a highly multifaceted role, since it is
involved in several nonmetabolic and metabolic conditions,
both physiological and pathological, including angiogenesis
and vascular permeability, cell differentiation, tumorigenesis,
glucose homoeostasis, lipidmetabolism, energy homeostasis,
wound healing, inflammation, and redox regulation [80].
3. ANGPTL4: A Regulative Role in
Glucose and Lipid Metabolism
As previously introduced, among the “pleiotropic” roles of
ANGPTL4, greater attention was focused on its involvement
in glucose and lipid metabolism regulation [81]. A positive
correlation between increased ANGPTL4 and NEFAs levels
in plasma of healthy subjects after dietary regimens has
been shown. Conversely, the negative energy balance caused
by fasting increases the hydrolysis of intracellular TG in
adipocytes and other peripheral tissues. This leads to an
increase in plasma NEFA levels [82].
Another recent work by Robciuc et al. showed the in-
volvement of ANGPTL4 in mediating the PPAR훿 effects
on LPL activity in fatty acid (FA) uptake, whereas the
effect of PPAR훿 activation on 훽-oxidation is independent of
ANGPTL4 [83]. Interestingly, the authors investigated also
the role played by ANGPTL4 in regulating LPL activity, not
only at the level of the surface of capillaries, highlighting the
intracellular lipase degradation [83]. Other studies tried to
better assess the cellular localization and molecular mech-
anisms underlying ANGPTL4 role in lipid metabolism, as
reported by Dijk et al. [84].These authors performed ex vivo
and in vivo studies on adipocytes and adipose tissue from
wild-type and ANGPTL4−/−mice, showing that ANGPTL4
stimulates LPL processing in the endoplasmic reticulum (ER)
leading to its intracellular degradation [84]. Another study
proposed that LPL regulation by ANGPTL4 occurs at cell
surface [85].
The homeostasis of lipidmetabolism is promoted through
the intervention of lipases, enzymes that counterbalance LPL
activity. Indeed, they hydrolyze stored TG, allowing adipo-
cytes to release FA. Starting from these evidences, an inter-
esting work by Koliwad et al. [78] showed that ANGPTL4 is a
direct glucocorticoid receptor (GR) target and is involved in
GR-dependent TGmetabolism. Indeed,ANGPTL4-nullmice
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showed lower plasma TG levels and increased ability to gain
weight compared tomice overexpressing the gene, suggesting
a role of ANGPTL4 in modulating TG homeostasis by
regulation of its expression [78].
Lichtenstein et al. [73] have well explained the correlation
between ANGPTL4 role and inhibition of LPL-mediated
plasma TG lipolysis. Thanks to studies derived from trans-
genic mice, the molecular mechanisms underlying mouse
blood TG were deeply revealed. Normally, LPL monomer is
associatedwith theN-terminal domain ofANGPTL4protein,
thus shifting the balance between LPL dimers andmonomers
towards the latter, causing LPL inhibition and, consequently,
determining the alteration of TG clearance from the plasma
and FFA uptake decrease into the peripheral tissues [73].
Another mechanism by which ANGPTL4 inhibits LPL
was proposed by Chi et al. These authors showed that
ANGPTL4 can bind and inactivate LPL complexed to GPI-
HBP1. Therefore, the ANGPTL4-mediated LPL inactivation
greatly reduces the affinity of LPL for GPIHBP1 [86] (Fig-
ure 3).
Considering the discussed role about ANGPTL4 in lipid
metabolism, a possible link of this angiopoietin-like protein
with obesity was investigated. Different murine models were
proposed, highlighting a significant role of this protein in
central regulation of energy metabolism [87]. More recently,
Robciuc et al. carried out an interesting study on homozygous
twins, in which a positive correlation between ANGPTL4
expression levels, adipose tissue hormone-sensitive lipase
(LIPE), and CGI-58 gene was shown, supporting the hypoth-
esis of the ANGPTLs’ involvement in promoting lipolysis of
adipocytes [88].
As previously reported, ANGPTL4 is mainly expressed
in tissues such as WAT, liver, and skeletal muscle. A recent
work by Alex et al. [89] highlighted protein expression also in
human colon adenocarcinoma cells.The authors investigated
the role of short-chain fatty acids (SCFA) in HT29 and T48
cell lines and showed an induction of ANGPTL4 synthesis by
SCFA through PPAR훾 receptor activation [89]. Furthermore,
long-chain fatty acids have been shown to induce ANGPTL4
production and secretion by PPAR훿 activation in skeletal
muscle cells [90].
As many scientific papers showed, several proteins,
including ANGPTL4, inhibit LPL. A recent study focused
the attention on the regulationmechanisms of another lipase,
that is, the pancreatic lipase (PL). Interestingly, Mattijssen et
al. suggested the involvement of ANGPTL4 also in endoge-
nous inhibition of dietary lipids, through knockout mice
experiments [91] (Figure 4).
However, ANGPTL4 is not the only angiopoietin-like
family member involved in maintaining energy metabolism
homeostasis. Other two members, such as ANGPTL3 and
ANGPTL8, can inhibit LPL activity by affecting plasma TG
levels. Indeed, different works showed overexpression of
these proteins inmice and humans with increased plasma TG
levels. Conversely, mutant mice carrying a loss-of-function
of ANGPTLs exhibited low plasma TG levels [32, 92–94],
although all three proteins show different tissue expression
patterns and are regulated by different stimuli.This has led to
the hypothesis that they are active during different metabolic
states.
A recent work by Zhang proposed an ANGPTL3-4-8
molecular model to explain TG trafficking specifically in
cardiac and skeletal muscles [95]. The model suggests that
feeding can induce ANGPTL8, resulting in the activation of
the ANGPTL3-8 pathway. This causes LPL inhibition and
increase in plasma levels of TG which can be stored in WAT.
In this district, decreases in ANGPTL4 concentration allow
an increased LPL activity.The opposite scenario is presented
during fasting.The impact of the ANGPTLs on plasma lipid
levels has led to considering them as therapeutic targets for
dyslipidemia [96].
Decreased plasma levels of this angiopoietin-like protein
have been detected also after insulin induction. A recent
study focused on the evaluation of the systemic effect of
insulin on LPL and its regulative machinery in subjects with
a different tolerance degree to insulin and showed a decrease
in the adipose tissue ANGPTL4 expression in type 2 diabetes
mellitus patients and healthy subjects [97].
Other evidences concerning the ANGPTL4 role in glu-
cosemetabolism regulation were reported in different studies
on transgenic mice, where the decrease of blood glucose,
improvement of glucose tolerance, and induction of hyper-
lipidemia and hepatic steatosis have been linked to the
protein [44, 98]. More recently, other studies carried out on
humans and animal models suggested the involvement of
ANGPTL4 in nephrotic syndrome, revealing that ANGPTL4
acts by linking proteinuria and hypertriglyceridemia through
negative feedback loops [99].
4. Role of ANGPTL4 in Cancer
The analysis of the different components of the tumor
microenvironment and their cross talk have been the focus
of the research of many molecular laboratories, especially
since a lot of studies showed the key role played by tumor
microenvironment in cancer development and progression.
In vivo and in vitro models affirmed the ability of different
molecular factors belonging to the tumor microenvironment
in regulating cell–cell and cell–matrix communications, cell
migration, invasion, and metastatic dissemination, but also
in conditioning drastically the efficacy of antitumor therapies
[100–102].
Currently, we know well that the malignance grade of a
tumor is related to several factors, including genomic instabil-
ity, heterogeneity (cells types such as fibroblasts, endothelial
cells, pericytes, and immune cells), and composition of the
microenvironment, which has been shown to change in
different cancer types and also among different patients
harbouring the same tumor histotype.
To date, the role of ANGPTL4 in cancer progression is
not well defined, and there is still some controversy in the
literature indicating the need of more studies addressing this
interesting topic.
Several studies identified the presence of ANGPTL4 in
various solid tumors, such as breast cancer, colorectal cancer,
prostate cancer, hepatocarcinoma, and renal cell carcinoma
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Figure 3:Molecularmechanism governingANGPTL4-mediated TGhydrolysis. LPLmonomer is linked to nANGPTL4 protein fraction, thus
shifting the balance between LPL dimers and monomers towards the latter. As a consequence, LPL is inhibited and this causes the alteration
of TG clearance from the plasma and uptake decrease of FFA into the peripheral tissues.The intervention of ANGPTL4 on LPL causes also
the reduction of LPL affinity for GPIHBP1 protein.
[103–107], suggesting its important role in cancer growth
and progression, anoikis resistance, altered redox regulation,
angiogenesis, and metastasis [80, 104, 108]. One potential
link between ANGPTL4 and tumorigenesis is provided by
hypoxia conditions, which represent a prominent feature of
tumor microenvironment. Indeed, hypoxia induces overex-
pression of cyclooxygenase-2 (COX-2) by hypoxia-inducible
factor-1 (HIF-1), an oxygen-sensitive transcriptional reg-
ulator [109–111], leading to the synthesis of prostanoids,
especially prostaglandins PGE2. COX-2 is upregulated in
recruited macrophages to trigger activation of other immune
cells involved in antitumor response. Increased levels of
PGE2 stimulate an intracellular signaling cascade leading
to the induction of the ANGPTL4 expression and cANG-
PTL4 secretion [112]. Although most of studies have not
explained the specific role played by ANGPTL4 as entire
molecule or generated fragments, currently, several evidences
suggested a prevalent activity of cANGPTL4. This fragment
seems to be involved in “anoikis resistance,” which is a
peculiar feature of metastatic cells acquiring ability to escape
programmed cell death. cANGPTL4 interacts with beta-
integrins to maintain an elevated ROS rate, inducing a redox-
based survival mechanism that involves the activation of the
SRC kinase and mitogen-activated protein kinase (MAPK)
signaling pathways favoring cancer cell growth and survival
[113].
As regards tumor angiogenesis, there are discordant data
about the proangiogenic or antiangiogenic role of ANGPTL4.
Several experiments showed that the ANGPTL4 increase by
HIF-훼 stimulates the secretion ofmultiple proangiogenic fac-
tors regardless of vascular endothelial growth factor (VEGF).
In this regard, one of the first evidences regards Kaposi’s sar-
coma, which is characterized by a deregulated angiogenesis
process promoted by the release of proangiogenic molecules.
Several in vitro and in vivo studies detected a significant
ANGPTL4 upregulation in endothelial cells expressing a
deregulated herpesvirus-8- (HHV-8- or KSHV-) encoded
G protein-coupled receptor (vGPCR), which is considered
a key factor in Kaposi’s sarcoma tumorigenesis. ANGPTL4
inhibition has been associated with a significant decrease of
neovascularization and vascular leakage in vitro and vGPCR-
mediated tumorigenesis in vivo [114–116]. However, other
studies have reported that ANGPTL4 exhibits an antian-
giogenic role, inhibiting the proliferation, chemotaxis, and
tubule formation of endothelial cells. One of such studies
explored the effects of ANGPTL4 on the mouse epidermis
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Figure 4: Regulation of expression and role of ANGPTL4 in lipid metabolism. In WAT, fasting induces ANGPTL4 expression through the
action of different molecules such as PPARs, HIF-1훼, and GR. The protein stimulates TG degradation via LPL inhibition. In liver, PPAR
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Also in intestine, FAs stimulate ANGPTL4 expression via one of the PPARs. ANGPTL4 produced by enterocytes is thus released towards the
lumen and inhibits pancreatic LP.
through an in vivo neovascularization assay, revealing that
ANGPTL4 decreased only VEGF-induced neovasculariza-
tion, whereas it was not able to influence VEGF-independent
neovascularization [27].
Finally, all these studies suggested that both proangio-
genic and antiangiogenic effects of ANGPTL4 are reliable and
strongly dependent on the related tumor microenvironment.
Several evidences suggested that tumor microenvironment
plays a crucial role in multiple steps of tumor develop-
ment and progression, including drug resistance, immune-
escaping, distant metastasis, and angiogenesis [117]. In par-
ticular, stromal cells are able to secrete multiple factors,
including ANGPTL4, to enhance vasculature permeability in
both lung and brain cancers [118].
Furthermore, asmentioned before, both the secretion and
proangiogenic activities of ANGPTL4 are highly dependent
on the vGPCR expression by the Kaposi Sarcoma tumor
microenvironment. A recent study carried out on patients
with uvealmelanoma (UM) showed thatANGPTL4 secretion
is regulated by HIF-1 and cooperates with VEGF in the
angiogenesis promotion, supporting the potential benefit
of a combined VEGF-ANGPTL4 inhibition to increase the
efficacy of antiangiogenic treatments [119–121]. In addition,
a recent work by Xin et al. [122] showed that HIF-1-induced
upregulation of ANGPTL4may promote vessel permeability
in ischemic retinopathies, such as diabetic eye. All these
evidences emphasize the need for further investigations
about the posttranslational modifications that ANGPTL4
can undergo, to better understand how generated fragments
could modulate pro- or anti-angiogenic events.
Some studies suggested that metastatic process seems
to be pushed by the activation of human ANGPTL4 via
TGF-훽.This protein is an essential multifunctional cytokine
involved in embryo development and tissue homeostasis but
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is secreted also in response to hypoxia and/or inflammation.
In particular, it has been shown to induce an increase in
human ANGPTL4 levels in breast cancer cells, by acti-
vating SMAD transcription factors, ultimately favoring the
transendothelial migration of tumor cells through disrup-
tion of endothelial cell junctions [104, 123]. In hepatocellu-
lar carcinoma cells, ANGPTL4 also favors transendothelial
migration and metastasis, through upregulation of vascular
cell adhesion molecule-1 (VCAM-1) on endothelial cells,
and stimulates the VCAM-1/integrin 훽1 signaling pathway,
facilitating the cancer cell transendothelial extravasation to
develop distant metastasis [124]. Another study concerning
the role of ANGPTL4 in colorectal cancer patients posi-
tively correlated ANGPTL4 expression and venous invasion,
which is considered the first step of metastatic process.
However, the biological mechanism remains elusive [104].
Finally, a study only showed that ANGPTL4 may prevent
tumor invasiveness and metastasis through modulation of
both endothelial and tumor cell cytoskeleton organization
[116]. Taken together, all these data suggest a potential
prometastatic role for ANGPTL4, which of course needs to
be deeply investigated in further studies, in order to elucidate
the biological mechanisms underlying these processes. Since
several studies suggested the involvement of ANGPTL4
in vascular permeability, angiogenesis, and inflammatory
processes, ANGPTL4-modulating agents, such as PPARs,
fatty acids, and specific drugs, could be useful for treatment
of associated diseases [125].
5. ANGPTL4 as Potential Modulator of the
Cross Talk between Metabolism and Cancer
Last decade has progressively evidenced two diseases, such as
diabetesmellitus and obesity, as contributing factors to cancer
onset and development. The first can favor tumor growth
by increasing the availability of nutrients (e.g., glucose and
FFA) or through alteration of the normal insulin signaling
machinery, that causes an increase in blood lipid concen-
trations [126, 127]. Moreover, FFAs themselves can favor
the instauration of oxidative stress through the formation
of stress molecules such as reactive oxygen species (ROS),
contributing to inflammation and tumor growth [128, 129].
The obesity could also be linked to cancer development
through regulative mechanisms linked to adipokines and
inflammatory cytokines [130, 131]. Indeed, obesity is char-
acterized by accumulation of visceral adipose tissue that
produces high quantities of inflammatory cytokines, mainly
leptin, but also IL-1훽, TNF-훼, IL-8, and IL-6 [74, 132]. In
adipocytes, PPAR훾 activation has been associated with the
upregulation of IRS-2 and CAP components of insulin path-
way and hence to increased insulin sensitivity [133]. In this
complex scenario, we speculated on the potential role played
by some “pleiotropic”molecules, such as PPARs isoforms and
ANGPTL4, in connecting lipid and glucose metabolism with
cancer.
As previously reported, PPARs activation depends on the
binding of different ligands. Among the PPAR ligands, there
are natural and synthetic compounds, such as fibrates and
thiazolidinediones, aimed at contrasting pathological condi-
tions, including the dyslipidemic state (hypertriglyceridemia)
and diabetes mellitus [134, 135].
An interestingwork by Sethi et al. [136] showed that LDLs
oxidation in endothelial cells causes their activation by PPAR
agonists. Other PPAR agonists, such as bezafibrate, have been
shown to directly improve insulin sensitivity through the
activation of PPAR훾 isoform [137].
As previously reported, the different PPAR isoforms are
involved in lipid metabolism with different mechanisms of
action, depending also on the tissue context in which they
are [4, 83, 138–142]. Their deregulation can be evidenced
in various tissue contexts. For example, an increase in
PPAR훽/훿 expression was associated with a decreased lipid
accumulation during a fat-rich diet in cardiac cells, whereas
its overexpression in intestine was linked to colon cancer
development [142]. Indeed, Sertznig et al. [4] showed that
colon cancer cell activation depends on the stimulus induced
by arachidonic acid, which leads to COX-2 upregulation
and overproduction of prostaglandin PGE2. As previously
reported, increased levels of PGE2 stimulate an intracellular
signaling cascade, leading to the induction of ANGPTL4
expression and cANGPTL4 secretion [112]. Furthermore,
macrophage PPAR훿 induced by Th2 cytokines released by
adipocytes has been shown to modulate the polarization of
adipose tissue-residentmacrophages, causing activation of an
anti-inflammatory phenotype and consequently improving
insulin sensitivity [143].
Also PPAR훾 is involved in lipid metabolism. Similar to
PPAR훽/훿 isoform, it regulates the activity of proteins like
LPL [139, 140]. Due to this evidence, probably ANGPTL4,
as well as other adipokines, is also a target of PPAR훾,
acting as a mediator of lipid metabolism. Moreover, PPAR훾
deregulation was detected not only in peripheral tissues
linked to lipid metabolism, but also in inflammation and
cancer [144]. Several evidences suggested that PPAR훾 ligands
may be potent inhibitors of angiogenesis mechanisms useful
for anticancer therapy [145, 146]. Trombetta et al. [147]
showed that fatty acids, such as docosahexaenoic acid (DHA),
activate PPAR훾 in cancer cells, leading to the inhibition
of tumor development. Moreover, studies carried out on
WAT, using long-chain monounsaturated fatty acids (LC-
MUFAs), revealed a PPAR훾 overexpression and a decrease of
inflammatory markers in diabetes syndrome [148].
The increasing recognition of the dynamic entity of
ANGPTL4 and its multifunctional role in different metabolic
and nonmetabolic pathways, the expression network linking
PPARs isoform to this angiopoietin-like protein, together
with the recent evidences of involvement of PPAR in can-
cer, led to do some significant speculations on the poten-
tial molecular cross talk between these molecules, lipid
metabolism, and cancer [149].
As previously reported, the ANGPTL4 expression de-
pends on different stimuli, such as hypoxia and fasting and,
finally, PPAR훽/훿 isoform induction [80]. Interestingly, recent
evidences showed that ANGPTL4 expression is activated by
PPAR훽/훿, not only in adipose tissue but also in response to
inflammation duringwound healing [70]. Indeed, ANGPTL4
was defined as novel matricellular protein interacting with
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specific ECM proteins and integrins to facilitate cell migra-
tion during this event [54, 69]. This specific function could
be linked to the C-terminal domain. Indeed, cANGPTL4
can activate 훽1 and 훽5 integrins, through their binding,
in order to regulate cell migration via the focal adhesion
kinase (FAK)/p21-activated kinase- (PAK-) signaling cascade
[69]. Huang et al. [150] demonstrated that cANGPTL4 may
induce vascular disruption through a direct and sequential
association with integrin 훼5훽1, VE-cadherin, and claudin-5,
favoringmetastasis. Other evidences showed that this protein
fragment can bind to specific matrix proteins and delay their
proteolytic degradation through the intervention of metallo-
proteinases [70]. Also, the endothelial ANGPTL4 secretion
induced by tumor-released semaphorin 4D (SEMA4D) has
been shown to modulate vascular permeability [151]. The
absence of ANGPTL4 in macrophages has been shown to
promote atherosclerosis, inducing foam cell formation and
vascular inflammation [152]. Conversely, Georgiadi et al.
[153] showed that ANGPTL4 overexpression reduces uptake
of oxidized low-density lipoprotein (oxLDL) bymacrophages
and inhibits foam cell formation in murine models, conse-
quently by counteracting the atherosclerosis development.
More recently, Goh et al. [70] reported that ANGPTL4 up-
regulation after inflammatory stimulus determines the regu-
lation of transcription factors involved in epidermal differen-
tiation, such as protein kinase C (PKC) and activator protein-
1 (AP-1).
Considering the similarities between the wound healing
and cancer microenvironment, it becomes clear how the
matricellular role ofANGPTL4 and its up- or downregulation
can be translated in the neoplastic cellular context. As
evidence of its role in cancer development, several scientific
works showed a mRNA deregulation pattern associated with
the tumor progression. Indeed, ANGPTL4 mRNA has been
found to be upregulated in the perinecrotic areas of different
tumor types [154, 155].
A deeper investigation needs to be conducted on the
roles played by different functional domains of ANGPTL4.
As previously described, togetherwith the full-length protein,
nANGPTL4 and cANGPTL4 fragments can also be detected
in plasma. Many scientific papers showed a different func-
tional role for each of these protein domains. nANGPTL
fragment seems to bemainly responsible for the regulation of
lipidmetabolism by inhibiting LPL activity, whereas a weaker
effect in modulating triglyceride availability seems to be
attributable also to flANGPTL4. Conversely, the cANGPTL4
fragment is involved in tumor cell growth, anoikis resistance,
angiogenesis inhibition, andwoundhealing, depending on its
interacting molecules [54] (Figure 5).
Interestingly, the different domains of ANGPTL4 and,
consequently, their different roles are correlated to the tissue
context in which they act. Obviously, this dependence is
linked also to the different partners interacting with the
various protein fragments. These evidences taken together
led to speculate on the evolutionary benefit of having one
protein with many functions correlated to distinct structural
domains.
6. Conclusions
Abundant evidences opened the way to speculate a potential
synergic role of PPARs and ANGPTL4 as key players in
the cross talk between metabolic syndromes and cancer
(Figure 6).
Indeed, as shown, (1) diabetes and obesity are impor-
tant cancer comorbidity factors; (2) PPARs are involved
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in lipid and glucose metabolism; (3) PPAR훾 and PPAR훽/훿
regulate the expression level of inflammatory cytokines and
adipokines, such as leptin and ANGPTL4; (4) the deregu-
lation of PPAR isoforms was detected in different types of
cancer; (5) the ANGPTL4 expression depends on the PPAR
stimulus. Considering all these points previously discussed,
it would be legitimate to hypothesize that ANGPTL4 tran-
scription regulation by PPARs constitutes a gateway between
obesity, insulin sensitivity, and cancer.
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